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MaMore than a decade ago, a formalized fellowship training program in medical device innovation, the ﬁrst of its kind, was
created at Stanford University. Now in its 15th year, the Stanford Biodesign Fellowship Program is a 10-month program
whereby postgraduate students with a prior background in medicine, engineering, and/or business form interdisciplinary
teams for an experiential process of identifying unmet clinical needs, inventing new solutions, and implementing these
ideas (the 3 “I’s”). A key component of this structured process is focused attention on needs ﬁnding and characterization,
which differs from the traditional “tech-push” model (i.e., technologies looking for problems to solve). Although the
Stanford Biodesign process can be applied to a wide variety of clinical areas, cardiovascular medicine is particularly well
suited, given the breadth of clinical presentations it touches and its history of innovation to solve important clinical
problems. Physicians play a vital role in the process, especially for needs identiﬁcation and characterization. This paper
outlines the Stanford Biodesign process and presents an argument for its repeat applicability, discusses its relevance to
physicians and to cardiologists in particular, and provides a case study of the process that resulted in a currently available
cardiovascular medical technology that came directly from the Fellowship Program. (J Am Coll Cardiol Basic Trans
Science 2016;1:541–7) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I nnovation and entrepreneurship have beenwidely celebrated in recent years, reaching asfar as mainstream television with multiple cur-
rent on-air shows (e.g., Silicon Valley, Shark Tank,
etc.). In parallel with this increased cultural aware-
ness, universities across the country have devel-
oped entrepreneurship training programs, initially
focusing on engineering, but more recently expand-
ing to the life sciences. One of the oldest life science
programs is Stanford Biodesign, which focuses on
training young innovators of biomedical technolo-
gies (particularly medical devices) (1). A primary
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an upfront focus on identifying and characterizing
the clinical need, rather than beginning with a prom-
ising technology. The central dogma of the Stanford
Biodesign process is that “a well-characterized need
is the DNA of a great invention” (2). This needs-
based approach to innovation begins in the clinical
environment, where practicing clinicians are ideally
placed to spearhead the process. Although many
companies have germinated from the fellowship pro-
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542apply this process serially to solve unmet
clinical needs.
The program is both ﬁeld- and technology-
agnostic but has deep roots in cardiovascular
medicine; the Stanford Byers Center for Bio-
design is directed by Dr. Paul Yock, aninterventional-trained cardiologist and serial entre-
preneur who invented the Rapid Exchange balloon
angioplasty/stenting system and intravascular ultra-
sound (3,4). In just 15 years of existence, more than
180 engineers, physicians, and business professionals
have completed the fellowship training, and nearly a
thousand students have taken undergraduate or
graduate courses in Biodesign. To date, 41 companies
have been launched by these ﬁrst-time innovators
directly from Stanford Biodesign, and many other
technologies have been invented by alums of the
program after graduation.
Currently, the fellowship group consists of 3
multidisciplinary teams of 4 fellows who follow
the “3 I’s” process each year (identify, invent, ande Stanford Biodesign Process
design process (3 I’s)—identify, invent, and implement—are outline
ften requires returning to prior stages and phases as new informa
ach step in the process. Reprinted with permission from Yock etimplement) (Figure 1) as they evaluate and solve
needs in a particular clinical area. Each phase is
described in detail in this paper.
PHASE 1: IDENTIFY—
CLINICAL IMMERSION, NEEDS FINDING
Shortly after the fellowship commences, the teams
begin an intensive needs-ﬁnding process. Approxi-
mately 20% of the fellowship time is devoted to this
vital stage, in which each team delves deeply into a
speciﬁc clinical area by direct immersion in relevant
inpatient and outpatient settings. Over the course of
several weeks, the fellows document their clinical
observations with the goal of creating a list of at least
200 needs.
The next step in the process is the development of
a need statement. This single sentence is carefully
crafted to capture the essence of the need. In effect, it
is a mission statement, serving as the driving force
behind the team’s efforts to solve the identiﬁed need.d, with 2 speciﬁc stages performed during each phase. The process is
tion becomes available through research. Key activities performed at
al. (4).
FIGURE 2 An Example of 2 Possible Need Statements
An example of 2 possible need statements from a fellowship group in the Stanford Biodesign Program. The need statement on the left contains a solution embedded
within the statement (a better stent), which limits the potential concepts that can fulﬁll this need statement. The need statement at right no longer contains an
embedded solution and instead places focus on the outcome (the consequences of emboli). Many more potential concepts that fulﬁll this revised need statement can
thus be brainstormed. Reprinted with permission from Yock et al. (4).
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543It encapsulates the clinical problem that has been
identiﬁed, the speciﬁc population afﬂicted by the
problem (which will serve as the focus of possible
solutions), and a measureable outcome that can be
affected by potential solutions. One particularly
important caveat in developing a need statement is
that a solution should not be inadvertently embedded
within the need statement, as this severely narrows
the range of potential solutions the team will consider
(see Figure 2 for an illustration of this issue for a
cardiovascular-related need). A well-crafted example
of a need statement from a team focused on a car-
diovascular need (discussed in detail in the case dis-
cussion in the following text) is:
A better way to detect potential rhythm dis-
turbances in nonhospitalized patients with
suspected arrhythmias to improve the patient
experience and reduce the cost of diagnosis.The large number of initial needs is then sub-
jected to a rigorous screening process to narrow the
list down to a few top needs. These ﬁlters include
the clinical impact of the need, the degree of
understanding of the pathophysiology involved, a
consideration of the existing and emerging clinical
approaches, and a preliminary assessment of the
market potential for a solution to this need (i.e.,
what might the value of a solution be to the health
system?). Again, physicians play a key role at this
stage because their understanding of pathophysi-
ology and current treatment methods helps the
screening process proceed efﬁciently. An additional
ﬁlter follows from an assessment of the stakeholders
with an interest in this needs area. The key question
for stakeholder analysis is: which parties (including
patients, providers, payers, regulators, and others)
stand to have an inﬂuence—positive or negative—on
whether a solution to a particular need will actually
FIGURE 3 Phase 1: Identify
In the ﬁrst phase of the process, the identify phase, needs ﬁnding is the primary focus. Many needs are recorded through clinical observations
and are then screened and ﬁltered down to those with the greatest opportunity and most interest. Reprinted with permission from
Yock et al. (4).
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544make it through to patient care? Once all of the
preceding information is compiled, the needs are
then ranked and prioritized with the goal of select-
ing the few most compelling needs to take further in
the process.
Once a screened list of contenders for the ﬁnal
needs is created, speciﬁc need criteria are developed
for each need based on further research and in-
terviews with stakeholders. The need criteria are a
relatively small set of key characteristics that a truly
successful solution should have to meet that need.
Typically, there are 3 to 6 “must-have” criteria and a
similar number of “nice-to-have” criteria. These need
criteria guide the team during all subsequent steps of
the Biodesign process. The background research
required to develop a well-crafted need statement
and list of criteria has a beneﬁcial effect on innova-
tion: it limits an innovator’s tendency to speed
through to the inventing process before developing a
deep understanding of the need, and it simulta-
neously provides a mechanism for objectively
assessing the true utility of a proposed solution
(Figure 3).
PHASE 2: INVENT—CONCEPT GENERATION
AND SCREENING, CREATIVITY
Once several promising needs have been identiﬁed,
clear need statements created, and accurate need
criteria have been developed, teams embark on the
inventing phase. Here, each team brainstorms anumber of concepts that could potentially meet the
need criteria. A robust brainstorming session of an
hour’s duration may create 50 to 60 (or more) con-
cepts. On closer consideration, however, a select few
of these concepts will truly meet the need criteria,
and a few subsequent brainstorming sessions are
usually required to generate a strong list of concepts
that meet the criteria, while also providing inter-
esting and potentially novel solutions. To aid orga-
nization of the brainstormed concepts, grouping into
similar categories (e.g., chemical means, biological,
mechanical, electrical, etc.) often proves fruitful. This
allows similar and overlapping ideas to either be
linked or eliminated, and it identiﬁes sparse areas
that need to be explored further.
At this point, a second screening process is applied
with the goal of ﬁltering concepts. The ﬁlters in this
case include intellectual property (IP), likely regula-
tory pathway, reimbursement potential, technical
feasibility, and viability of the business model needed
to bring the solution to patients. The considerations
involved in these ﬁlters are often complex, and it may
require several weeks or more to conduct sufﬁcient
research to ﬁnd clarity in each category for a partic-
ular solution. Customarily, teams will rate the degree
of difﬁculty each ﬁlter represents: IP may have a clear
path (a “green light”), for example, but the regulatory
pathway may be worrisome enough from a standpoint
of time and risk to merit a caution (“yellow light”)
ranking. This careful ﬁltering process generally
provides the team with a short list of top concepts,
FIGURE 4 Phase 2: Invent
During the second phase of the process (invent), concepts are created after multiple brainstorming sessions. These concepts are then subjected
to a rigorous screening process that leads to ﬁnal concept selection. Reprinted with permission from Yock et al. (4).
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545reducing the tally of 10 to 15 promising solutions
emanating from brainstorming to a list of the top 2
or 3 (Figure 4).
Next, serious prototyping of the top concepts can
begin. Efﬁcient and effective prototyping must be
question driven, and multiple iterations of prototypes
are typically created for each concept. In some cases,
even these early prototypes will be sufﬁciently
advanced to provide the basis for pre-clinical testing,
either on the benchtop or in an animal model. This
early-stage testing, coupled with further research,
will in most cases point to 1 or 2 concepts as clear
frontrunners.PHASE 3: IMPLEMENT—COMMERCIALIZATION
POTENTIAL, STRATEGY DEVELOPMENT
The top 1 or 2 concepts have now undergone
rigorous background research and have survived a
rigorous ﬁltering process. In-depth analysis of each
concept is undertaken to formulate a plan to pro-
ceed. This includes a comprehensive understanding
of the IP landscape, a plan for a credible reim-
bursement pathway, as well as an understanding of
the engineering feasibility, resources, and personnel
needed to undergo further research and develop-
ment. A detailed plan for device testing is then
FIGURE 5 A Novel Single-Use, 14-Day Cardiac Event Monitor
This device is an example of a successful medical device initially
conceived by a fellowship group in the Stanford Biodesign
Program. It is currently commercially available in the United
States and Europe.
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546devised, including pre-clinical and clinical trials, as
well as a quality management protocol. A viable
business model must then be created, which in-
cludes understanding sales and distribution, ﬁnan-
cial modeling, funding strategies (i.e., venture
capital, corporate funding, government grants, and
so on), and marketing and stakeholder strategy
(creating a value proposition). The competitive
advantage of the proposed concept over the existing
competition is a pillar of a successful product
launch, and alternative commercialization plans
must also be considered.
CASE STUDY: A SINGLE-USE,
14-DAY CARDIAC EVENT MONITOR
Of the more than 40 companies that have come
out of Stanford Biodesign at least 5 have stemmed
from physicians with formal training in cardiovas-
cular medicine (5). One is Dr. Uday N. Kumar, a
cardiac electrophysiologist (EP) who currently serves
on the faculty in Biodesign. As a Biodesign fellow,
he and his team focused on the EP ﬁeld and iden-
tiﬁed more than 200 needs. One need in particular—
the detection of potential arrhythmias in nonhospit-
alized patients—rose to the top of the ﬁltering
process (see the need statement in the preceding
text). The team brainstormed a number of solutions
and screened these against the categories described
earlier in this paper.
After ﬁltering of a number of concepts, the top
solution was a long-term (up to 14 days), water-
resistant, disposable patch-based monitor to iden-
tify cardiac arrhythmias. Shortly after the fellowship
concluded, Dr. Kumar formally incorporated a
company and licensed the technology from Stanford
University to develop the concept as part of a
complete solution, including a cloud-based algo-
rithm and robust supporting service. The device
is currently commercially available (Figure 5). To
date, the device has been used on nearly 500,000
patients, and several publications have docu-
mented the clinical and economic utility of the
approach (6).
The Stanford Biodesign process played an instru-
mental role in the development of the new cardiac
event monitor, especially during the identify phase of
the Biodesign process. First, the intense focus on
tracing needs to their root as part of needs ﬁnding
led the team to understand that a misalignment of
care existed. The team identiﬁed that although car-
diac rhythm monitors are typically prescribed by
cardiologists and electrophysiologists (who are alsothe treatment providers), patients with possible
arrhythmias typically ﬁrst present to primary care
providers or the emergency department, where high-
quality, specialized testing for arrhythmias is usually
not available. Second, based on a detailed under-
standing of existing solutions, the team identiﬁed
that current diagnostic testing for cardiac arrhyth-
mias had a multitude of problems, including many
nondiagnostic results and poor patient adherence.
Third, by performing a rigorous stakeholder analysis,
it was clear that even though primary care providers
and emergency physicians would need a very simple
and easy-to-deploy device to initiate testing, at the
same time, cardiologists and cardiac EPs would need
very detailed and accurate data to devise a proper
treatment plan. With these 3 insights, a ﬁnal solution
emerged that provided a way to reduce the number
of nondiagnostic and unnecessary repeat tests,
empowered frontline providers with an easy-to-use
device to initiate testing, allowed for patients to
easily adhere with the test as prescribed, and gener-
ated a robust report for specialists to make an accu-
rate treatment plan. Thus, a prolonged effort in the
identify phase of the Biodesign process resulted in a
well-vetted need that signiﬁcantly improved the
likelihood for success.
SUMMARY
Cardiovascular medicine is a rapidly changing,
innovation-centric ﬁeld with deep roots in medical
technology that is perfectly suited for application of
a disciplined innovation curriculum. The Stanford
Biodesign process described here provides a step-
wise approach to creating new biomedical technol-
ogies that begins with deep diligence into clinical
needs. Physicians, and cardiologists in particular,
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547encounter countless clinical needs each day; the
Biodesign process provides a standardized protocol
to turn this need identiﬁcation into action. Utilizing
this process, needs eventually lead to solutions that
not only advance the ﬁeld but also directly beneﬁt
patients.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Paul G. Yock, Stanford University School of Medicine,
Stanford Byers Center for Biodesign, 318 Campus
Drive, Stanford, California 94305-5428. E-mail:
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